Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity
D. Biswas, L. Slade, L. Duffley, N. Mueller, K. T. Dao, A. Mercer, S. Pakkiriswami, Y. El-Hiani, P. Kieneseberger, T. Pulinilkunnil
Abstract
Triple-negative breast cancers (TNBCs) are characterized by poor survival, prognosis and gradual resistance to cytotoxic chemotherapeutics, like doxorubicin (DOX), which is limited by its cardiotoxic and chemoresistant effects that manifest over time. TNBC growth and survival are fuelled by reprogramming branched-chain amino acids (BCAAs) metabolism, which rewires oncogenic gene expression and cell signaling pathways. A regulatory kinase of the rate-limiting enzyme of the BCAA catabolic pathway, branched-chain ketoacid dehydrogenase kinase (BCKDK), have recently been implicated in driving tumor cell proliferation and conferring drug resistance by activating RAS/RAF/MEK/ERK signaling. However it remains unexplored if BCKDK remodels TNBC proliferation, survival and susceptibility to DOX-induced genotoxic stress. TNBC cell lines exhibited reduced BCKDK expression in response to DOX. Genetic and pharmacological inhibition of BCKDK in TNBC cell lines displayed reduced intracellular and secreted BCKAs. Moreover, BCKDK inhibition with concurrent DOX treatment exacerbated apoptosis, caspase activity and loss of TNBC proliferation. Transcriptome analysis of BCKDK silenced cells confirmed a marked upregulation of the apoptotic signaling pathway with increased protein ubiquitylation and compromised mitochondrial metabolism. BCKDK silencing in TNBC downregulated mitochondrial metabolism genes, reduced electron complex protein expression, oxygen consumption and ATP production. Silencing BCKDK in TNBC upregulated sestrin 2 and concurrently decreased protein synthesis and mTORC1 signaling. Inhibiting BCKDK in TNBC remodel BCAA flux, reduces protein translation triggering cell death, ATP insufficiency and susceptibility to genotoxic stress. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=137 SRC="FIGDIR/small/444634v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@19d375eorg.highwire.dtl.DTLVardef@9dfe2corg.highwire.dtl.DTLVardef@9a1eecorg.highwire.dtl.DTLVardef@642fdb_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells
Dorian V. Ziegler, Kanishka Parashar, … Lluís Fajas·Nature CommunicationsPeer-reviewed·Jan 9, 2025
- BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators
O. Castellanet, F. Ahmad, … F. Maina·bioRxiv·Mar 16, 2021
- Mitochondrial translation is a targetable dependency of chemo-refractory triple negative breast cancer
Mariah J. Berner, Steven W. Wall, … Gloria Vittone Echeverria·bioRxiv·Apr 18, 2026
- Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy
R. C. Geck, J. R. Foley, … A. Toker·bioRxiv·Jan 8, 2020
- Quiescent OXPHOS-high triple-negative breast cancer cells that persist after chemotherapy depend on BCL-XL for survival
Sławomir Andrzejewski, Marie Winter, … Eugen Dhimolea·CellsPeer-reviewed·Oct 8, 2025
- A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer
Qiyun Deng, Mehdi Amiri, … Nahum Sonenberg·bioRxiv·Sep 16, 2026